Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer
Dateline City:
KENILWORTH, N.J.
Data from Pivotal Phase 3 Trial Showed KEYTRUDA Plus Chemotherapy Reduced the Risk of Disease Progression or Death by 35% Compared to Chemotherapy Alone as First-Line Treatment in Patients with Metastatic TNBC Whose Tumors Expressed PD-L1 (CPS ≥10)
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 KEYNOTE-355 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (mTNBC).
Language:
English
Contact:
Media:
Pamela Eisele
(267) 305-3558
or
Ayn Wisler
(908) 740-5590
Investors:
Peter Dannenbaum
(908) 740-1037
or
Courtney Ronaldo
(908) 740-6132
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
